FBIO vs. LXRX, ACHV, RGLS, AGEN, SABS, CRIS, BOLT, MTEM, AMGN, and GILD
Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), Regulus Therapeutics (RGLS), Agenus (AGEN), SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), and Gilead Sciences (GILD). These companies are all part of the "biotechnology" industry.
Fortress Biotech vs.
Lexicon Pharmaceuticals (NASDAQ:LXRX) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.
Lexicon Pharmaceuticals received 153 more outperform votes than Fortress Biotech when rated by MarketBeat users. Likewise, 64.69% of users gave Lexicon Pharmaceuticals an outperform vote while only 63.62% of users gave Fortress Biotech an outperform vote.
Lexicon Pharmaceuticals has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.
Lexicon Pharmaceuticals currently has a consensus target price of $6.00, indicating a potential upside of 769.57%. Fortress Biotech has a consensus target price of $13.67, indicating a potential upside of 630.84%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Fortress Biotech.
Fortress Biotech has a net margin of -84.53% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. Fortress Biotech's return on equity of 0.00% beat Lexicon Pharmaceuticals' return on equity.
74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 4.5% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 33.4% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Fortress Biotech has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
In the previous week, Fortress Biotech had 3 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 3 mentions for Fortress Biotech and 0 mentions for Lexicon Pharmaceuticals. Fortress Biotech's average media sentiment score of 0.30 beat Lexicon Pharmaceuticals' score of -0.63 indicating that Fortress Biotech is being referred to more favorably in the news media.
Summary
Fortress Biotech beats Lexicon Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Fortress Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fortress Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:FBIO) was last updated on 1/20/2025 by MarketBeat.com Staff
